- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA clears Fuji DRC algorithm
The Food and Drug Administration has granted regulatory clearanceto Fuji Medical Systems for its dynamic range control (DRC) algorithm,which improves the performance of the company's computed radiographysystems. Fuji unveiled DRC at the 1993 Radiological
The Food and Drug Administration has granted regulatory clearanceto Fuji Medical Systems for its dynamic range control (DRC) algorithm,which improves the performance of the company's computed radiographysystems. Fuji unveiled DRC at the 1993 Radiological Society ofNorth America meeting (SCAN 2/2/94).
DRC enables physicians to improve the resolution of bone orsoft tissue on CR images, according to the company. DRC uses alocally adaptive histogram equalization algorithm to improve visualizationof dense structures and soft tissue. Since debuting DRC at the1993 meeting, Fuji has improved the technology to allow bettervisualization of both bone and soft tissue on the same image.The earlier version of DRC was not able to enhance both typesof structures at the same time.
The FDA clearance allows Fuji, of Stamford, CT, to offer DRCto its installed base of AC-1, AC-2 and FCR 7501 CR readers. Fujiis still awaiting the agency's word on DRC for its next-generationreaders, which include AC-3, FCR 9000 and FCR 9501.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
